Moderna, Inc.

Company facts

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

Cambridge, Massachusetts

Most recent report

8-K, filed Sep 1, 2026

Incorporated

Delaware

Filings on record

1,003+ filings

On EDGAR

CIK 1682852

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 3 of 9 sections worth reading, with 0 positive, 7 notable, and 3 negative flags.

• Item 1

  Core financials: $950M settlement, $1.5B debt, widening losses, new product approvals.
  Notable

  • $1.5B facility with $600M drawn at ~9.2% interest, secured by substantially all assets.
  • Fourth product approved in EU; not yet generating sales as of June 30, 2026.
  • Cash and investments down $1.2B to $6.91B from $8.14B since Dec 2025, funding operations.
  Negative

  • $950M settlement paid in July; up to $1.3B additional payment if appeal fails.
  • Norovirus vaccine trial failed early success hurdle; remains blinded with additional enrollment.

• Legal Proceedings (Item 1)

  New company-specific litigation from Sanofi filed July 2026.
  Negative

  • New patent suit from Sanofi (July 2026) over COVID and RSV vaccines, damages unspecified.

• Other Information (Item 5)

  Multiple executives adopted 10b5-1 plans for large option exercises, a change from Q2 2025.
  Notable

  • CEO terminated a plan for up to 751,715 shares and adopted a new plan for expiring options covering 1.39 million shares.
  • President Hoge adopted plan to sell shares from 917,431 options plus cover costs on remaining 1.38 million expiring options.
  • Director Hussain adopted plan for a one-time sale of 2,930 shares to cover tax obligations on vesting.
  • CLO Klinger adopted plan to exercise and sell up to 31,805 shares between Sep 2026 and Sep 2027.

What changed: Jun 2026 vs. Mar 2026

About 9% of MRNA's Jun 2026 10-Q is new information. 25 paragraphs were added, 131 changed, and 25 removed. Below are the most important lines SECSift identified.

• Item 1 99
• Item 5 8
• Item 4 2
• Item 6 1
• Item 3 1
• Item 2 1